Vaxart, Inc. (VXRT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Vaxart, Inc. (VXRT) Healthcare & Pipeline Overview

Vaxart, Inc. is a clinical-stage biotechnology firm pioneering oral recombinant protein vaccines across various infectious diseases and therapeutic areas. Leveraging its proprietary oral vaccine platform, the company is advancing a pipeline of tablet-based candidates for norovirus, influenza, RSV, and coronavirus, aiming to address significant global health challenges through novel delivery mechanisms.

What Is the Investment Thesis for VXRT?

Vaxart, Inc. presents an investment thesis centered on its innovative oral recombinant protein vaccine platform, which offers a differentiated approach to vaccine delivery with significant market potential. The company's pipeline, including candidates for norovirus (Phase Ib), seasonal influenza (Phase II), RSV, and coronavirus (Phase II), targets large global health markets. The oral tablet format could provide competitive advantages in terms of administration ease, distribution logistics, and potential for broader immune responses, including mucosal immunity, which is critical for respiratory and gastrointestinal pathogens. Key value drivers include the successful progression of its clinical pipeline through advanced stages, particularly the Phase II trials for influenza and coronavirus, and the Phase Ib for norovirus. Positive clinical data readouts could significantly de-risk the platform and attract partnerships or licensing agreements. The company's current financial metrics, such as a robust Profit Margin of 14.5% and ROE of 53.1%, despite being a clinical-stage company, suggest efficient capital deployment in its R&D efforts. A relatively low Debt-to-Equity ratio of 12.96 also indicates a healthy balance sheet. The potential for first-in-class oral vaccines in major disease areas represents substantial commercial upside, contingent on regulatory approvals and market adoption. However, the inherent risks of clinical-stage biotechnology, including trial failures, regulatory hurdles, and intense competition, remain critical considerations for investors.

Based on FMP financials and quantitative analysis

VXRT Key Highlights

• Vaxart maintains a market capitalization of $126M, reflecting its valuation as a clinical-stage biotechnology company with significant future potential tied to pipeline success.
• The company reported a Profit Margin of 14.5%, which is notable for a biotechnology firm primarily focused on research and development, indicating effective cost management or specific revenue streams.
• Vaxart's Gross Margin stands at 21.7%, suggesting a foundational level of profitability from any existing operations or early-stage collaborations, while still heavily investing in its pipeline.
• With an ROE of 53.1%, Vaxart demonstrates a high level of efficiency in generating profits from shareholders' equity, a strong indicator of management's ability to create value.
• A Debt-to-Equity ratio of 12.96 indicates a relatively low reliance on debt financing, providing financial flexibility and a less leveraged capital structure compared to many industry peers.

Who Are VXRT's Competitors?

VXRT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VXRT's Key Strengths?

• Proprietary oral vaccine platform offers a differentiated delivery mechanism.
• Diverse clinical pipeline targeting multiple high-impact infectious diseases and therapeutic areas.
• Potential for improved patient compliance and simplified logistics with tablet vaccines.
• Strong financial metrics for a clinical-stage company, including 14.5% Profit Margin and 53.1% ROE.

What Are VXRT's Weaknesses?

• Clinical-stage company with no currently approved commercial products, leading to reliance on R&D success.
• Significant capital requirements for ongoing clinical trials and future commercialization efforts.
• High regulatory hurdles and lengthy development timelines inherent to vaccine development.
• Limited geographic reach, primarily operating from its South San Francisco headquarters.

What Could Drive VXRT Stock Higher?

• Norovirus Vaccine Phase Ib Data Readout: The anticipated release of data from the Phase Ib clinical trial for Vaxart's bivalent oral tablet norovirus vaccine (GI.1 and GII.4 strains) is a significant near-term catalyst. Positive safety and immunogenicity results could validate the platform and accelerate further clinical development.
• Seasonal Influenza Vaccine Phase II Progress: Continued advancement and potential interim or final data readouts from the Phase II clinical trial for the seasonal influenza vaccine (H1 infection) could provide crucial insights into its efficacy and safety profile, driving investor confidence.
• Coronavirus Vaccine Phase II Data: The ongoing Phase II clinical trial for the SARS-CoV-2 oral vaccine is a key catalyst. Successful progression and the announcement of positive clinical data would be critical for its future development and potential market positioning.
• Initiation of RSV Vaccine Clinical Trials: The formal initiation of clinical trials for Vaxart's respiratory syncytial virus (RSV) vaccine candidate would mark a significant step, signaling progress in addressing another major global health challenge and expanding the pipeline's value.
• Strategic Partnerships or Licensing Agreements: As pipeline candidates mature, the announcement of strategic collaborations or licensing agreements with larger pharmaceutical companies for late-stage development, manufacturing, or commercialization could provide substantial non-dilutive funding and market validation.

What Are the Key Risks for VXRT?

• Financial-distress signal — its Altman Z-Score of -0.14 sits in the distress zone (elevated bankruptcy risk).
• Clinical Trial Failure: As a clinical-stage biotechnology company, Vaxart faces the inherent risk that its vaccine candidates, including those for norovirus, influenza, RSV, and coronavirus, may fail to demonstrate sufficient safety or efficacy in ongoing or future clinical trials, leading to development termination.
• Regulatory Approval Hurdles: Even with positive clinical data, there is a significant risk of delays or outright denial of regulatory approvals by health authorities (e.g., FDA) due to unforeseen issues, stringent requirements, or evolving guidelines for novel vaccine technologies.
• Intense Competition: The vaccine market is highly competitive, with numerous established pharmaceutical companies and emerging biotechs developing vaccines for similar indications. Vaxart's oral vaccines may face challenges in demonstrating superior efficacy, safety, or market acceptance compared to existing or competing injectable products.
• Funding and Capital Requirements: Vaxart's continued operations and advancement of its extensive clinical pipeline are highly dependent on securing substantial additional funding. There is a risk that the company may not be able to raise sufficient capital on favorable terms, leading to delays or curtailment of R&D programs.
• Intellectual Property Challenges: The company's success relies on its ability to protect its proprietary oral vaccine platform and specific vaccine candidates through patents. There is a risk of intellectual property infringement, challenges to patent validity, or the inability to obtain new patents, which could undermine its competitive position.

What Are the Growth Opportunities for VXRT?

• Advancement of Norovirus Vaccine Program: Vaxart's oral tablet norovirus vaccine, currently in a Phase Ib clinical trial for bivalent GI.1 and GII.4 strains, represents a significant growth opportunity. Norovirus is a leading cause of acute gastroenteritis globally, with an estimated 685 million cases and 200,000 deaths annually, creating a substantial market need for an effective vaccine. Successful progression through clinical trials and eventual regulatory approval could position Vaxart as a pioneer in addressing this widespread public health issue with a convenient, needle-free solution. The ease of administration and potential for mucosal immunity could provide a competitive edge in a market currently lacking an approved norovirus vaccine.
• Commercialization of Seasonal Influenza Vaccine: The company's seasonal influenza vaccine, in Phase II clinical trials for H1 influenza infection, targets a massive and recurring global market. The annual influenza vaccine market is valued in the tens of billions of dollars, driven by seasonal vaccination campaigns. An oral tablet vaccine could significantly enhance vaccination rates by overcoming needle phobia and simplifying distribution logistics, especially in regions with limited healthcare infrastructure. Positive Phase II and subsequent Phase III data, leading to regulatory approval, would allow Vaxart to tap into this established market with a differentiated product offering, potentially capturing a meaningful share due to its unique delivery method.
• Development of Respiratory Syncytial Virus (RSV) Vaccine: Vaxart's RSV vaccine candidate addresses another critical respiratory pathogen, particularly impactful on infants and the elderly. The global RSV vaccine market is projected to reach several billion dollars in the coming years, with recent approvals highlighting the significant demand. While specific clinical trial stages for Vaxart's RSV candidate were not detailed in the source, its inclusion in the pipeline signifies a strategic pursuit of a high-value market. Successful development and clinical validation of an oral RSV vaccine could offer a compelling alternative to existing or emerging injectable options, leveraging the benefits of oral administration for widespread adoption.
• Progression of Coronavirus Vaccine Program: The coronavirus vaccine, currently in Phase II clinical trial for SARS-CoV-2 infection, represents a continued opportunity in a market that has seen unprecedented global demand. While multiple injectable vaccines are available, an oral tablet vaccine could offer distinct advantages, including ease of booster administration, broader accessibility, and potential for mucosal immunity, which could be crucial for preventing infection and transmission. Successful completion of Phase II and subsequent trials, leading to regulatory approval, would allow Vaxart to enter a market that, despite existing options, continues to seek improved and more convenient vaccination methods, especially for endemic phases of the virus.
• Expansion into Therapeutic HPV Vaccines: Vaxart is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus (HPV). This initiative represents a strategic diversification beyond infectious disease prevention into oncology and therapeutic vaccines. The global market for HPV vaccines is substantial, driven by prevention efforts, but therapeutic vaccines for existing HPV infections and associated pre-cancers or cancers represent a distinct and growing market segment. Successful development of an oral therapeutic HPV vaccine could provide a non-invasive treatment option, offering a significant improvement over current surgical or ablative procedures and addressing a critical unmet medical need for millions affected by HPV-related conditions.

What Opportunities Does VXRT Have?

• Potential for first-in-class oral vaccines for norovirus, RSV, and therapeutic HPV.
• Expansion into new therapeutic areas leveraging the versatility of the oral vaccine platform.
• Strategic partnerships or licensing agreements with larger pharmaceutical companies for late-stage development and global distribution.
• Addressing global health challenges with accessible, easy-to-distribute vaccines, particularly in underserved regions.

What Threats Does VXRT Face?

• Clinical trial failures or unexpected adverse events halting pipeline progression.
• Intense competition from established pharmaceutical companies with extensive vaccine portfolios.
• Regulatory setbacks or delays in obtaining approvals for vaccine candidates.
• Market acceptance challenges for a novel oral vaccine platform compared to traditional injectables.

What Are VXRT's Competitive Advantages?

• Proprietary Oral Vaccine Platform: Vaxart's core competitive advantage is its unique oral recombinant protein vaccine platform, enabling tablet-based delivery which differentiates it from traditional injectable vaccines.
• Mucosal Immunity Potential: Oral vaccines may induce mucosal immunity, offering a distinct advantage for respiratory and gastrointestinal pathogens by protecting at the primary site of infection, potentially offering superior protection.
• Logistical Advantages: The tablet format simplifies distribution, storage (reduced cold chain requirements), and administration, potentially lowering costs and increasing accessibility globally compared to injectable vaccines.
• Diverse Clinical Pipeline: A pipeline targeting multiple high-impact diseases (norovirus, influenza, RSV, coronavirus, HPV) demonstrates the versatility and broad applicability of its platform, diversifying potential revenue streams.

What Does VXRT Do?

Vaxart, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California, dedicated to the discovery and development of novel oral recombinant protein vaccines. The company's core innovation lies in its proprietary oral vaccine platform, which aims to transform vaccine administration from traditional injections to convenient, tablet-based forms. This approach seeks to offer advantages such as easier distribution, reduced cold chain requirements, and potentially broader immune responses, including mucosal immunity. Founded with the vision of making vaccines more accessible and effective, Vaxart has strategically focused its research and development efforts on high-unmet medical need areas. Its product pipeline is robust, featuring several candidates in various stages of clinical development. A key program is the norovirus vaccine, an oral tablet vaccine currently undergoing a Phase Ib clinical trial. This bivalent vaccine targets the prevalent GI.1 and GII.4 norovirus strains, which are major causes of acute gastroenteritis worldwide. Beyond norovirus, Vaxart is also advancing a seasonal influenza vaccine, which is in a Phase II clinical trial for the treatment of H1 influenza infection, aiming to provide a needle-free alternative to existing flu shots. The company’s pipeline further includes a respiratory syncytial virus (RSV) vaccine candidate, addressing another significant respiratory pathogen, and a coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. In addition to infectious diseases, Vaxart is exploring therapeutic applications, developing vaccines for cervical cancer and dysplasia caused by human papillomavirus (HPV), highlighting its platform's versatility. With a team of 105 employees, Vaxart operates as a focused biotech entity, striving to bring its innovative oral vaccine technology from clinical development to commercialization, potentially reshaping the future of vaccine delivery and global health.

What Products and Services Does VXRT Offer?

• Discovers and develops oral recombinant protein vaccines.
• Utilizes a proprietary oral vaccine platform for tablet-based delivery.
• Advances a norovirus vaccine in Phase Ib clinical trials.
• Develops a seasonal influenza vaccine in Phase II clinical trials.
• Researches a respiratory syncytial virus (RSV) vaccine candidate.
• Progresses a coronavirus vaccine in Phase II clinical trials.
• Develops therapeutic vaccines for cervical cancer and dysplasia caused by HPV.
• Aims to provide needle-free vaccination alternatives for various diseases.

How Does VXRT Make Money?

• Primarily focused on research and development (R&D) of novel vaccine candidates through clinical trials.
• Potential future revenue generation through licensing agreements and partnerships with larger pharmaceutical companies for late-stage development and commercialization.
• Future direct sales of approved oral vaccines to healthcare providers, governments, and public health organizations.
• Monetization of intellectual property through patents related to its oral vaccine platform and specific vaccine candidates.

What Industry Does VXRT Operate In?

Vaxart, Inc. operates within the highly dynamic and innovation-driven biotechnology industry, a sub-sector of the broader healthcare sector. This industry is characterized by extensive research and development, lengthy clinical trial processes, and significant regulatory oversight. The global vaccine market, a key focus for Vaxart, is experiencing robust growth driven by increasing prevalence of infectious diseases, rising awareness of preventative healthcare, and technological advancements in vaccine development. The market for infectious disease vaccines alone is projected to reach substantial figures, with oral vaccines representing a niche but rapidly expanding segment due to their potential for improved patient compliance and simplified logistics. Vaxart's proprietary oral vaccine platform positions it within the competitive landscape of vaccine developers, differentiating itself through its tablet-based delivery mechanism. While traditional injectable vaccines dominate, the pursuit of needle-free alternatives, especially for widespread diseases like influenza and norovirus, places Vaxart at the forefront of a potentially transformative trend. The company competes with established pharmaceutical giants and other biotech firms developing novel vaccine technologies, necessitating continuous innovation and successful clinical execution to capture market share.

Who Are VXRT's Key Customers?

• Patients seeking convenient, needle-free vaccination options for infectious diseases like influenza, norovirus, RSV, and coronavirus.
• Healthcare systems and providers looking for easier-to-administer vaccines with potentially improved patient compliance.
• Governments and public health organizations interested in scalable, logistically simpler vaccine solutions for mass vaccination campaigns and pandemic preparedness.
• Individuals with HPV-related cervical cancer or dysplasia, seeking non-invasive therapeutic vaccine options.

Net sellingInsider Activity

Over the past six months, Vaxart, Inc. insiders filed 14 SEC Form 4 transactions — 11 sales and 3 purchases. On net that is roughly 67K shares disposed (about $89K), a signal worth weighing alongside the fundamentals.

FY2026 estForward Outlook

Wall Street analysts project Vaxart, Inc. revenue of about $200.5M for fiscal 2026, with EPS near $-0.18.

F-Score 5/9Financial Health

Vaxart, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.14 places it in the distress zone, a signal of elevated financial risk.

ROE 61%Key Financial Metrics

Return on equity for Vaxart, Inc. stands at 61.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 20.6%, showing how much profit it generates from its asset base. VXRT trades at a trailing price-to-earnings ratio of 3.69, below the Healthcare sector average of ~23x. Its free cash flow yield is 10.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.71 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 25.7%, the inverse of the P/E and a quick read on earnings relative to price.

Vaxart, Inc. (VXRT) Valuation Context

Valued at $126M, VXRT is classified as a micro-cap stock. Relative to its peer group, VXRT's quantitative score of 48/100 is below the peer average of 75/100.

Company Profile

Vaxart, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Steven Lo. VXRT has traded publicly since 1981.

VXRT Financials

VXRT Latest News

VXRT Analyst Consensus

VXRT MoonshotScore

Common Questions About VXRT (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources